Focused On-demand Library for 1,5-anhydro-D-fructose reductase

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Aldo-keto reductase family 1 member C-like protein 2; Aldo-keto reductase family 1 member E2; LoopADR; Testis aldo-keto reductase; Testis-specific protein

Alternative UPACC:

Q96JD6; Q86Z16; Q86Z17; Q86Z18; Q9BU71


1,5-anhydro-D-fructose reductase, known by its recommended name and alternative names such as Aldo-keto reductase family 1 member C-like protein 2 and Testis-specific protein, plays a crucial role in metabolic processes. It catalyzes the NADPH-dependent reduction of 1,5-anhydro-D-fructose to 1,5-anhydro-D-glucitol, showcasing its enzymatic activity in carbohydrate metabolism. This protein also exhibits reductase activity towards specific substrates like 9,10-phenanthrenequinone, highlighting its versatility in biochemical reactions.

Therapeutic significance:

Understanding the role of 1,5-anhydro-D-fructose reductase could open doors to potential therapeutic strategies. Its involvement in key metabolic pathways underscores its importance in maintaining cellular homeostasis and energy balance, making it a target of interest for drug discovery efforts aimed at metabolic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.